Bristol Myers Q2 2026 adjusted EPS $2.04 beats $1.46 year-over-year; company raises FY 2026 guidance to $6.75–$7.00 adjusted EPS and $49.8–$50B revenue.
LiveSquawk07/30, 06:22 PM
- Adj EPS $2.04
- $1.46 Y/Y
- Rev. $12.97B
- $11.74B
Figures as quoted by LiveSquawk
Related assets
Coming up for BMY
Explore next
Latest BMY news
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.
Finnhub08/04, 12:17 AM
Finnhub08/03, 10:50 PM